Similar articles

• The quest for the in medio stat virtus price in the oncology sector.

  Petrou P. Petrou P. J Med Econ. 2018 Oct;21(10):1023-1025. doi: 10.1080/13696998.2018.1499520. Epub 2018 Aug 1. J Med Econ. 2018. PMID: 29992848 No abstract available.
• Targeted immunotherapies overtaking emerging oncology market value based growth.

  Jakovljevic MB. Jakovljevic MB. J BUON. 2015 Jan-Feb;20(1):350-1. J BUON. 2015. PMID: 25778340 No abstract available.
• Dying to survive and cancer care in China.

  Lucas C. Lucas C. Lancet Oncol. 2019 Jan;20(1):30. doi: 10.1016/S1470-2045(18)30921-5. Lancet Oncol. 2019. PMID: 30614464 No abstract available.
• Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

  MacLeod TE, Harris AH, Mahal A. MacLeod TE, et al. Patient. 2016 Jun;9(3):201-22. doi: 10.1007/s40271-015-0139-7. Patient. 2016. PMID: 26370257 Review.
• Pharmaceutical costs. An overview and analysis of legal and policy responses by the states.

  Latham SR. Latham SR. J Leg Med. 2003 Jun;24(2):141-73. doi: 10.1080/713832157. J Leg Med. 2003. PMID: 12775406 Review. No abstract available.